What is the appropriate meropenem dosing regimen for a patient receiving dialysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Meropenem Dosing in Dialysis Patients

For patients on intermittent hemodialysis, administer meropenem at half the recommended dose (250 mg for skin/soft tissue infections or 500 mg for intra-abdominal infections) every 24 hours, given after each dialysis session. This recommendation is based on the FDA-approved dosing for severe renal impairment 1.

Dosing by Dialysis Modality

Intermittent Hemodialysis (IHD)

The FDA label provides clear guidance for patients with creatinine clearance <10 mL/min 1:

  • Complicated skin/soft tissue infections: 250 mg every 24 hours
  • Intra-abdominal infections: 500 mg every 24 hours
  • Timing: Administer doses immediately after dialysis sessions to avoid premature drug removal

Critical caveat: The FDA label explicitly states "there is inadequate information regarding the use of meropenem in patients on hemodialysis" 1, yet provides these dosing recommendations based on pharmacokinetic principles.

Continuous Renal Replacement Therapy (CRRT)

For critically ill patients receiving CRRT, the optimal regimen is 750 mg every 8 hours regardless of whether they're receiving continuous venovenous hemofiltration (CVVH) or continuous venovenous hemodialysis (CVVHD) 2, 3. This applies to both standard (20-25 mL/kg/h) and high (35 mL/kg/h) effluent rates.

Recent population pharmacokinetic studies support 500 mg every 8 hours or 1 gram every 12 hours for patients with acute kidney injury on continuous hemodiafiltration (CHDF), targeting bacteria with MIC ≤2 mg/L 4.

Prolonged Intermittent Renal Replacement Therapy (PIRRT)

For PIRRT, dosing depends on session frequency and duration 5:

Alternate-day PIRRT:

  • Most session durations: 1000 mg loading dose, then 500 mg every 8 hours
  • 10-hour hemodialysis sessions: 1000 mg every 12 hours

Daily PIRRT:

  • Hemodialysis (4-8 hour sessions): 750 mg every 8 hours
  • Hemodialysis (10-hour sessions): 1000 mg every 8 hours
  • Hemofiltration varies by duration: 500 mg every 8 hours (4-hour) to 750 mg every 8 hours (10-hour)

Peritoneal Dialysis

For automated peritoneal dialysis (APD), intraperitoneal administration of 750 mg daily is optimal for pathogens with MIC 2-8 mg/L 6. This dosing achieves adequate concentrations in both plasma and dialysate without significant drug accumulation.

The FDA label notes "data currently are not available for patients receiving peritoneal dialysis" 1, but tuberculosis guidelines suggest starting with hemodialysis doses and verifying adequacy through therapeutic drug monitoring 7.

Key Clinical Considerations

Pharmacodynamic targets: Meropenem requires free drug concentrations above the MIC for 40% of the dosing interval (40% fT>MIC) for bacteriostatic effect, and ideally 100% fT>MIC for optimal bactericidal activity 2, 4.

Timing with dialysis: Always administer meropenem immediately after hemodialysis sessions to prevent premature drug removal and facilitate directly observed therapy 7.

Therapeutic drug monitoring: Given the significant pharmacokinetic variability in dialysis patients, therapeutic drug monitoring is strongly encouraged when available, particularly for:

  • Patients with residual renal function
  • Those receiving CRRT or PIRRT
  • Infections with organisms having higher MICs (4-8 mg/L)
  • Critically ill patients with altered volumes of distribution 8, 4

Residual renal function: Patients with residual creatinine clearance >50 mL/min receiving CRRT may have significantly increased meropenem clearance (up to fivefold), potentially requiring dose adjustments 8.

Common pitfall: Do not use standard dosing in dialysis patients—meropenem is significantly removed by dialysis and accumulates in renal failure, risking both treatment failure (underdosing) and neurotoxicity including seizures (overdosing) 1.

References

Research

Population pharmacokinetics of meropenem in patients undergoing automated peritoneal dialysis.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.